The protein tyrosine phosphatase non-receptor type 7 (PTPN7), also known as hematopoietic protein tyrosine phosphatase (HePTP), is a member of the protein tyrosine phosphatase (PTP) family. It plays a regulatory role in immune cell signaling by dephosphorylating key kinases in mitogen-activated protein kinase (MAPK) pathways, particularly in T-cells and myeloid cells. PTPN7 is critical for maintaining immune homeostasis, as it modulates activation thresholds and prevents excessive inflammatory responses. Antibodies targeting PTPN7 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate PTPN7's role in hematopoietic malignancies, autoimmune diseases, and immune dysregulation. Research has linked dysregulated PTPN7 expression to conditions such as acute myeloid leukemia (AML) and rheumatoid arthritis, highlighting its potential as a therapeutic target or biomarker. Commercial PTPN7 antibodies are typically validated for specificity against human or murine isoforms, with applications spanning basic research, drug development, and diagnostic assays. Ongoing studies aim to clarify its interactions with signaling partners and its impact on immune tolerance mechanisms.